WO2001070258A1 - COMPOSITION PHARMACEUTIQUE POUR EXCIPIENT POUR PRODUITS A BASE DE VITAMINE E, DE BROMELINE ET D'HYALURONIDASE - Google Patents

COMPOSITION PHARMACEUTIQUE POUR EXCIPIENT POUR PRODUITS A BASE DE VITAMINE E, DE BROMELINE ET D'HYALURONIDASE Download PDF

Info

Publication number
WO2001070258A1
WO2001070258A1 PCT/BR2001/000026 BR0100026W WO0170258A1 WO 2001070258 A1 WO2001070258 A1 WO 2001070258A1 BR 0100026 W BR0100026 W BR 0100026W WO 0170258 A1 WO0170258 A1 WO 0170258A1
Authority
WO
WIPO (PCT)
Prior art keywords
epitheliums
permeability
coating
epithelium
cells
Prior art date
Application number
PCT/BR2001/000026
Other languages
English (en)
Inventor
Empreendimentos E Participações S/C Ltda. Topic
Original Assignee
Santana, Cristiano, Alberto, Ribeiro
De Nucci, Gilberto
Falci, Marcio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santana, Cristiano, Alberto, Ribeiro, De Nucci, Gilberto, Falci, Marcio filed Critical Santana, Cristiano, Alberto, Ribeiro
Priority to PCT/BR2001/000026 priority Critical patent/WO2001070258A1/fr
Priority to AU46259/01A priority patent/AU4625901A/en
Publication of WO2001070258A1 publication Critical patent/WO2001070258A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases

Definitions

  • the present invention refers to a new pharmaceutical composition applicable under any form, most notably gel, cream, liquid, spray, aerosol, lyophilized of a carrier . substance for products to aggregate vitamin-E, bromeline and hyaluronidase .
  • the above . mentioned pharmaceutical composition is of topical application, non- toxic and features a high penetration rate through the skin.
  • the skin permeability varies according to the region of the body, being the skin folds and the face those that present the highest absorption rate. A product applied over the skin will present a longer period of contact and percutanial absorption.
  • the epithelium cells are. predominantly classified into two categories, which correspond to two epithelium classes: coating epithelium cells and secreting epithelium cells.
  • the cells of these two classes mix with each other to constitute, respectively, the coating epithelium and the secreting epithelium, each one of them performing specific functions that are inherent to .them.
  • Such division is also fundamented in the distribution of these two classes of epithelium in the organism., which although wide is distinctive for both.
  • the epithelium cells associate side-by-side, so as to originate "membranes” or layers superimposed over the base membrane, which function is to coat surfaces.
  • the secreting cells unite to form organized functional units, better suited for performing their specialized function, related to the secretion products synthesis; thus are constituted the secreting units.
  • the coating epitheliums are defined as living membranes, usually featuring a discontinuity, that isolate the organism from the environment, separating the internal media from the external one. Furthermore, these epitheliums isolate from each other the various internal media compartments, among which are the intravascular compartment, the serum compartment and several others.
  • the coating epitheliums are performed by specialized variants that are specifically adapted to perform one or more functions . Others are incorporated as general functions presented without distinction by every coating epithelium cell.
  • the coating epithelium cell in the same way as most of the living cells, passively absorbs water and electrolytes and eliminates them actively; this function is well developed in the epithelium cells . On that account it is very important to observe that generally it is understood as absorption the penetration of solutions through the cells plasmatic membrane.
  • the coating epithelium cells limit in a controlled and selective way the permeability of the respective epitheliums, with the purpose of protecting the organism and still participate of the control of its homeostasis.
  • the epitheliums are organized and arrange their cells in a special form, in order to build up coatings which cells abut the base membrane and are united with each other by means of intracellular junctions; in turn the cells are coated by the plasmatic membrane, which features special characteristics, and by the glicochalice, both able to express well defined functional properties.
  • the functional characteristics expressed by the plasmatic membrane portion that coats the cells apical surface are different from those expressed by the portion situated in its basal or basolateral face; such differences, which occur mainly on the functional aspect, contribute for the remarkable degree of polarization expressed by the coating epithelium cells .
  • the prime function performed by the coating epitheliums correspond essentially to the protection rendered to the surface that they coat, characterizing their protective coating function. Such function features a special characteristic, being a coating that, besides offering mechanical, physical and chemical protection to the coated surface, is not inert.
  • the coating epitheliums are pervious, which allows for the controlled and selective passage of several products through its wall.
  • the coating epitheliums permeability constitutes a fundamental property, with significant functional expression, for it is essential for the performance of several functions featured by the epitheliums, even more so because it is selective and its permeability degree presents a wide variation. It is fairly well demonstrated that the permeability degree influences strongly the function performed by the coating epitheliums :
  • the epitheliums allow intense metabolic exchanges through their walls, with poor control and selectivity of its permeability.
  • the epithelium acts on the filtration and transfer of metabolytes, these functions requiring little qualitative control; the exercise of these functions is subordinated to the epithelium intrinsic structure, which is adapted to act, mainly passively, being low the level of selective permeability.
  • these coating epitheliums present selective permeability, which allows them to interfere and qualitatively control their functional activity, as well as making them more able to actuate over the homeostasis control.
  • the absence of epithelium permeability is correlated to the complex isolation of the coated surface and, on the other hand, to the better controlling of this epithelium function, because its cells, although very poorly pervious, present selective permeability.
  • the coated surface has its boundaries limited by a "membrane" impervious or very poorly pervious and very effective, that performs an important protective function, for it is able to discriminate exactly what can cross the epithelium.
  • the coating epitheliums permeability is such an expressive functional property that it has been used as an important classification criterion to rank them in three classes:
  • the epitheliums Because of their selective permeability, even in the inferior animals the epitheliums have assumed the function of coating the organism, constituting its external coating, with limiting and protective properties, not only morphological but also functional. Their cells, in principle very similar, behaved as a semi-pervious "membrane" poorly effective that acted passively, but which function allowed the separation, tough precarious and more morphological than functional, between the internal and the external media. It seem to be that the majority of the coating epitheliums acts as a barrier that prevents the free passive diffusion, because their permeability, which is selective, is conditioned to several factors among which stands out the electric potential present in their cells plasmatic membrane.
  • the continuity of the epithelium coating is established as much through the intimate abutment of adjacent cells as through the presence of intercellular union devices.
  • the epithelium cells are enveloped by the glicochalice, that also takes part of the coating function performed by the epithelium, in addition to aid the union between adjacent cells, because the intracellular adhesive is formed also by the glicochalice.
  • glicochalice that also takes part of the coating function performed by the epithelium, in addition to aid the union between adjacent cells, because the intracellular adhesive is formed also by the glicochalice.
  • Several experimental investigations confirm that the coating epitheliums selective permeability is associated to other specific functions expressed by their cells, namely: absorption, excretion and secretion. These functions, beyond their permeability, which constitutes their prime function, are responsible by the general functioning of the epithelium cell.
  • the general functions performed by the coating epitheliums are basically the following: 1) surfaces protective coating function;
  • the first four derive mostly from the epithelium cells selective permeability, over which are additionally superimposed the additional affects corresponding to their properties of absorption, excretion and secretion.
  • the selective permeability is responsible by the efficiency regarding the ability to coat, protect and isolate the surfaces, as well as to effect the control of the homeostasis; the passive absorption and the metabolytes transfer capacity are executed normally by the majority of the cells of these epitheliums, which demand only minor adaptations to become able to effectively perform such functions.
  • the functions of absorption, excretion and secretion depend of properties that develop successively and would become paramount, mostly in some specialized types of coating epithelium, which adapted following a new and specific direction.
  • the sensorial perception and the germinative function are more specific functions that are only manifest by certain epitheliums even more specialized.
  • the coating epitheliums have been classified according to the same number of cellular extracts they bear in: simple (a single extract) and stratified (two or more extracts) . Both the simple epitheliums and the stratified ones, conforming to their cells format, are in turn subdivided into pavimentous, cubic or prismatic.
  • the simple epitheliums are usually adapted to manifest wholly their most expressive fundamental property that consists in their permeability, which degree and selectivity vary.
  • the simple coating epitheliums constituted by a single layer of pavimentous or cubic-prismatic cells, present major differences regarding their functional properties, correlated not only to their cell's morphology, but also to the intracellular space's properties.
  • the simple pavimentous epitheliums are usually very pervious; the cubic-prismatic ones are less pervious.
  • the coating epitheliums permeability, in addition to being selective, is controlled by their cell's functional activity, although the control looses efficiency in the same order as the intracellular space's permeability increases.
  • the cubic-prismatic epitheliums being less pervious than the pavimentous, are more effective to control their permeability.
  • the simple coating epitheliums are divided into two classes: pavimentous and cubic-prismatic . Each class is subdivided according to its functional properties in open or pervious epitheliums, in semi-occlusive or poorly-pervious and occlusive or impervious.
  • the cubic epitheliums and the prismatic epitheliums are usually considered distinct, being defined and identified according to the format of the epithelium cells that make them up.
  • some functional studies have showed that the correlation between form, and function presents several exceptions. For this reason a functional classification is adopted considering predominantly it's permeability.
  • these epitheliums are denominated cubic-prismatic comprising the semi-occlusive and occlusive epitheliums.
  • the stratified epitheliums can be subdivided into: pavimentous and cubic- prismatic.
  • the stratified epitheliums are adapted to perform primarily the mechanical protection function, because they are impervious or poorly pervious.
  • the epitheliums comprise, in addition to the cells, the intercellular space and the base membrane, which interfere in their permeability degree; their permeability derives not only from their cell's peculiar properties, responsible for the transcellular permeability way, but also from the presence of another permeability way of their walls, constituting the intercellular or paracellular way.
  • the transcellular way comprises two different ways that consist of the transmembranous way and the transcannular or trancitose way.
  • the coating epitheliums can be transposed by water and by substances of various natures, both through their epithelium cells (transcellular way) and through the way situated between their cells (intercellular way) .
  • the epithelium cell can effect the permeability control of the epithelium through its biological activity, making this process selective.
  • the intercellular way permeability the epithelium cell, although not behaving in a totally passive form, does not interfere directly in the transport selectivity.
  • the sole form of cell active participation comprises the determination, exceptionally, the enlargement of the corresponding intercellular space.
  • the epithelium cell By means of the action of the microfilaments that constitute its cito-skeleton, the epithelium cell, specially those of certain types of simple coating epitheliums pavimentous of the open type, can change its format and retract segments of its cytoplasm; thus being able to influence the size of the intercellular space and regulate it. It has been established that the transcellular permeability of the simple coating epitheliums is perfectly distinct from the intercellular permeability, because both are subordinated to very different mechanisms. The epithelium cell permeability, which is selective, is influenced by its biological activity; on the contrary, the intercellular permeability is totally passive, and thus is not selective.
  • the transcellular permeability of the simple coating epitheliums can be exercised through two distinct and independent ways : the transmembrane way, which is the true transcellular way, and the transcannular way, which happens through the vesicles and the cannules or tubes of the vesicle-cannular system, found inside the cytoplasm of many types of coating epithelium cells". Consequently, the coating epitheliums are pervious, which allows the controlled and selective passage of various products through its wall. It is demonstrated that the permeability degree affects strongly the coating epitheliums function. Three types of coating epitheliums are thus considered: 1- Of wide permeability;
  • the purpose is to prove through the formulation that there is an intense metabolic exchange demonstrating that the epithelium actuates on the transfer of metabolytes. This penetration of substances is complete and gradual and trespasses these epithelium layers until it penetrates the small blood vessels, reaching the circulatory current .
  • Bromeline is the generic name given to the protheolitic enzymes found on pineapple (Ananas comosus Mer. ) , as well as in other species of plants from the family Bromeliaceae.
  • the bromelines hydrolyze proteins, peptides, esters and amides. Its specificity and use are relatively similar to that of other proteases, such as papaine and fycine, extracted from latex of papaya and fig, respectively.
  • Bromeline is also similar to papaine when it comes to its activation and deactivation mechanism as a sulphidrilyc protease, that is, its enzymatic action depends o the sulphidrilyc group of a cisteyne residue.
  • Pineapple is the only fruit that features relatively high concentrations of proteases in the ripe state. In papaya, the papaine is only found in high levels when the fruit is still green.
  • raw material for the obtention of bromeline different parts of the plant can be used: leaves, stems, fruit juice, skin and industrial residues.
  • the most commonly used raw material is the ripe pineapple plant stems, used after the harvesting of the fruit. This raw material is easily available thanks to the plantation turnover .
  • the bioequivalence examination was carried out for the substance bromeline, resulting in parity from 1% to 1% between bromeline and papaine.
  • the object of the present invention is a "PHARMACEUTICAL COMPOSITION OF CARRIER SUBSTANCE FOR PRODUCTS BASED ON VITAMIN-E, BROMELINE AND HYALURONIDASE".
  • the current technique comprises in the pharmaceutical composition of the carrier substance the following formulation:
  • the penetration relation equals to 100% of the required cream.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention a trait à une nouvelle composition pharmaceutique pour excipient pour produits à base de vitamine E, de broméline et d'hyaluronidase dont la formulation est la suivante : plus de 0,1 % de broméline, plus de 0,1 % d'hyaluronidase de 50 à 900 utr/mg - et de 10 à 2000 mg de vitamine E.
PCT/BR2001/000026 2001-03-19 2001-03-19 COMPOSITION PHARMACEUTIQUE POUR EXCIPIENT POUR PRODUITS A BASE DE VITAMINE E, DE BROMELINE ET D'HYALURONIDASE WO2001070258A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/BR2001/000026 WO2001070258A1 (fr) 2001-03-19 2001-03-19 COMPOSITION PHARMACEUTIQUE POUR EXCIPIENT POUR PRODUITS A BASE DE VITAMINE E, DE BROMELINE ET D'HYALURONIDASE
AU46259/01A AU4625901A (en) 2001-03-19 2001-03-19 Pharmaceutical composition of carrier substance for products based on vitamin-E,bromeline and hyaluronidase

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/BR2001/000026 WO2001070258A1 (fr) 2001-03-19 2001-03-19 COMPOSITION PHARMACEUTIQUE POUR EXCIPIENT POUR PRODUITS A BASE DE VITAMINE E, DE BROMELINE ET D'HYALURONIDASE

Publications (1)

Publication Number Publication Date
WO2001070258A1 true WO2001070258A1 (fr) 2001-09-27

Family

ID=3946481

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2001/000026 WO2001070258A1 (fr) 2001-03-19 2001-03-19 COMPOSITION PHARMACEUTIQUE POUR EXCIPIENT POUR PRODUITS A BASE DE VITAMINE E, DE BROMELINE ET D'HYALURONIDASE

Country Status (2)

Country Link
AU (1) AU4625901A (fr)
WO (1) WO2001070258A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026335A1 (fr) * 2002-09-19 2004-04-01 Santana Cristiano Alberto Ribe Composition pharmaceutique renfermant des supports de produits
WO2004087197A1 (fr) * 2003-04-01 2004-10-14 Santana Cristiano Alberto Ribe Procede de production de medicament, vecteur correspondant et utilisation de ce medicament

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH630803A5 (en) * 1977-06-03 1982-07-15 Berema Sa Medicinal preparations, for the treatment of hypercholesterolaemia in particular
WO1997003676A1 (fr) * 1995-07-21 1997-02-06 Cabo Soler Jose Nouvelle formulation pharmaceutique de dehydroepiandrosterone pour application topique percutanee
DE19724458A1 (de) * 1997-06-10 1998-12-24 Mucos Pharma Gmbh & Co Verwendung proteolytischer Enzyme zur Verbesserung der Absorption von Arzneimitteln

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH630803A5 (en) * 1977-06-03 1982-07-15 Berema Sa Medicinal preparations, for the treatment of hypercholesterolaemia in particular
WO1997003676A1 (fr) * 1995-07-21 1997-02-06 Cabo Soler Jose Nouvelle formulation pharmaceutique de dehydroepiandrosterone pour application topique percutanee
DE19724458A1 (de) * 1997-06-10 1998-12-24 Mucos Pharma Gmbh & Co Verwendung proteolytischer Enzyme zur Verbesserung der Absorption von Arzneimitteln

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026335A1 (fr) * 2002-09-19 2004-04-01 Santana Cristiano Alberto Ribe Composition pharmaceutique renfermant des supports de produits
WO2004087197A1 (fr) * 2003-04-01 2004-10-14 Santana Cristiano Alberto Ribe Procede de production de medicament, vecteur correspondant et utilisation de ce medicament

Also Published As

Publication number Publication date
AU4625901A (en) 2001-10-03

Similar Documents

Publication Publication Date Title
US20240091332A1 (en) Compounds and methods for biofilm disruption and prevention
MX2007006074A (es) Composicion de desbridamiento a partir de bromelaina y metodos de produccion de la misma.
KR20050083758A (ko) 안정화된 산화환원 특성을 나타내는 조성물 및 그 안정화방법
WO2000053193A1 (fr) Composition pharmaceutique contenant une source de nitrate et un agent acidifiant pour le traitement d'une ischemie cutanee
EP1284750B1 (fr) Composition pharmaceutique
da Silva et al. Partial purification of fibrinolytic and fibrinogenolytic protease from Gliricidia sepium seeds by aqueous two-phase system
EP1303298B1 (fr) Composition pharmaceutique comprenant des transporteurs de produits actives pharmacologiques dont les transporteurs sont base a vitamine e, de papaine et d'hyaluronidase
WO2001070258A1 (fr) COMPOSITION PHARMACEUTIQUE POUR EXCIPIENT POUR PRODUITS A BASE DE VITAMINE E, DE BROMELINE ET D'HYALURONIDASE
US20060034824A1 (en) Pharmaceutical composition comprising carriers for products
US20030103955A1 (en) Diclofenac pharmaceutical composition based on vitamin-e, papain and hyaluronidase
EP1263460B1 (fr) Composition comprenant un support pharmaceutique et destinee a des produits a base de papaine
US20040146494A1 (en) Papaine containing pharmaceutical formulation resp its use
WO2003018063A1 (fr) Composition d'une substance d'excipient destinee a des produits a base de papaine et d'hyaluronidase
WO2002074329A1 (fr) Composition pharmaceutique appliquee au traitement de la maladie de la peyronie et son procede de production
WO2004087197A1 (fr) Procede de production de medicament, vecteur correspondant et utilisation de ce medicament
KR100489731B1 (ko) 피브로넥틴 및 βｉｇ-ｈ3의 일부 도메인을 포함하는 재조합 단백질을 함유하는 창상치료, 세포부착, 이동 및 증식 촉진용 약학적 조성물
WO2003015811A1 (fr) Procede permettant d'obtenir une composition pharmaceutique
RU2535053C2 (ru) Фармацевтическая композиция, содержащая лизин и ферменты: лизоцим, дезоксирибонуклеазу и/или пероксидазу для наружного лечения и профилактики инфекций, вызванных вирусом герпеса типа 1,2 и бактериальных осложнений, вызываемых герпетической инфекцией
WO2009137897A1 (fr) Nanoparticules contenant des enzymes protéolytiques destinées au traitement de la maladie de la peyronie

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN CZ HU ID IL IN IS JP KR MX NO NZ PL TR US